Atomoxetine (Strattera®), a potent and selective inhibitor of the presynaptic norepinephrine
transporter, is used clinically for the treatment of attention-deficit hyperactivity disorder (ADHD…

The role of the polymorphic cytochrome P450 2D6 (CYP2D6) in the pharmacokinetics of
atomoxetine hydrochloride [(−)-N-methyl-γ-(2-methylphenoxy)benzenepropanamine …

Objective: Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder
in children, adolescents, and adults. This study was conducted, in part, to evaluate the …

The purpose of this study was to characterize the effect of potent CYP2D6 inhibition by
paroxetine on atomoxetine disposition in extensive metabolizers. This was a single‐blind, two‐…

The effect of AKI and modern continuous RRT (CRRT) methods on drug disposition (pharmacokinetics)
and response has been poorly studied. Pharmaceutical manufacturers have little …

To determine whether physicians can adequately titrate atomoxetine without knowing genotype
status for hepatic cytochrome P 450 2D6, we pooled data from two open-label studies of …

Background: Selective kappa opioid receptor antagonism is a promising experimental
strategy for the treatment of depression. The kappa opioid receptor antagonist, LY2456302, …

In the studies reported here, the ability of atomoxetine hydrochloride (Strattera) to inhibit or
induce the metabolic capabilities of selected human isoforms of cytochrome P450 was …

Despite peptide transporter 1 (PEPT1) being responsible for the bioavailability for a variety
of drugs, there has been little study of its potential involvement in drug-drug interactions. …

Pomaglumetad methionil (LY2140023) is the prodrug of a novel metabotropic glutamate 2/3
receptor agonist (LY404039) being investigated for the treatment of schizophrenia. Using …